Breaking Research News from Breastcancer.org

Moderators

More Evidence That Chemotherapy Before Surgery Can Make Triple-Negative Breast Cancer Eligible for Lumpectomy
January 15, 2020
About half of women diagnosed with early-stage triple-negative breast cancer who were not eligible for lumpectomy when first diagnosed became eligible for lumpectomy after neoadjuvant chemotherapy. Read more...

Moderators

FDA Says Diet Medicine Belviq May Be Linked to Increase in Cancer Risk
January 17, 2020
The weight management medicine Belviq may possibly be linked to an increase in cancer risk, according to an FDA announcement on Jan. 14, 2020. Read more...

Moderators

FDA Approves Nerlynx for HER2-Positive Metastatic Breast Cancer
March 4, 2020
On Feb. 25, 2020, the FDA approved Nerlynx (chemical name: neratinib) in combination with Xeloda (chemical name: capecitabine) to treat advanced or metastatic HER2-positive breast cancer that has been treated with two or more anti-HER2 therapies. Read more...

Moderators

Many Young Women Have Financial Problems After Breast Cancer Diagnosis, Even With Insurance
March 9, 2020
Many women younger than 40 diagnosed with breast cancer have money problems after being diagnosed, even if they have stable jobs with health insurance benefits. Read more...

Moderators

Fast Breast MRI Seems to Find More Cancers in Dense Breasts Than 3D Mammogram
March 11, 2020
A 10-minute breast MRI exam, also called Fast Breast MRI, found more cancers than 3D mammograms in women with dense breasts. Read more...

Moderators

Weight Gain After Breast Cancer Diagnosis May Be a Bigger Issue Than Thought in Australia
March 13, 2020
Gaining weight after being diagnosed with breast cancer may be a bigger problem than previously thought in Australia. Read more...

Moderators

Support Organizations Important to Black Women Diagnosed With Breast Cancer in Memphis
March 17, 2020
Community-based support organizations are essential in helping black women in Memphis who have been diagnosed with breast cancer overcome barriers to care. Read more...

Moderators

ASCO Issues Guidelines on Managing Male Breast Cancer
March 18, 2020
Because not much research has been done on male breast cancer specifically, ASCO guidelines recommend managing it much the same way breast cancer is managed in women. Read more...

Moderators

BRCA Mutations More Common Than Thought in Older Women Diagnosed With Breast Cancer
March 18, 2020
Even though they had no family history that would make them eligible for genetic testing, about 1 in 40 postmenopausal women diagnosed with breast cancer before age 65 had a mutation linked to cancer in the BRCA1 or BRCA2 gene, a rate similar to Ashkenazi Jewish women. Read more...

Moderators

3D Mammograms Outperform Traditional 2D Mammograms, Five-Year Study Shows
March 20, 2020
A study with 5 years of data has found that compared to traditional 2D mammograms, 3D mammograms find more breast cancers and offer fewer false positives. Read more...

Moderators

New Guidelines on Managing Hereditary Breast Cancer
April 15, 2020
Three professional organizations have put out guidelines on how to treat and manage breast cancer in people with a genetic mutation linked to a higher risk of the disease. Read more...

Moderators

Adding Xeloda to Standard Chemotherapy After Surgery for Triple-Negative Breast Cancer Seems to Improve Outcomes
April 17, 2020
A Chinese study suggests adding Xeloda to the standard chemotherapy regimen after early-stage triple-negative breast cancer surgery improves disease-free survival without causing any new side effects. Read more...

Moderators

FDA Approves Tukysa for Advanced-Stage HER2-Positive Breast Cancer
April 17, 2020
On April 17, 2020, the FDA approved Tukysa in combination with Herceptin and Xeloda to treat metastatic HER2-positive breast cancer, or locally advanced HER2-positive disease that can't be completely removed with surgery, after the cancer had been treated with at least one anti-HER2 medicine. Read more...

Moderators

FDA Approves Trodelvy for Metastatic Triple-Negative Breast Cancer
April 22, 2020
On April 22, 2020, the FDA granted accelerated approval to Trodelvy to treat adults diagnosed with metastatic triple-negative breast cancer who have received at least two previous treatments for metastatic disease. Read more...

Moderators

Chemotherapy for Certain Small, Hormone-Receptor-Positive, HER2-Positive Breast Cancers Seems to Improve Survival
May 7, 2020
When looking at treatment outcomes for small, node-negative, hormone-receptor-positive, HER2-positive breast cancers, a study suggests that women diagnosed with cancers 8-10 mm in size had better survival when they were treated with chemotherapy after surgery, compared to women diagnosed with smaller cancers. Read more...

Moderators

Hi All, We are wondering how many of you read our research news articles.

We're thinking of getting a group together to get some feedback.

Would you PM us Mods to let us know if you do? Thank you!

redhead403

I do have an interest, but I am RN. I'm sure there are many that aren't interested

Lisey

I read all the news articles that apply to me. Usually this thread is just 'formalizing' info the other ladies have been discussing in other threads, but it lends a degree of authority to have y'all publish it.

lala1

I read everything that applies to me or my friends and I appreciate every article!

Moderators

Keytruda Plus Chemotherapy Offers More Benefits Than Chemo Alone as First Treatment for Metastatic Triple-Negative Breast Cancer With High Levels of PD-L1
May 14, 2020
Keytruda plus chemotherapy offered better progression-free survival than chemotherapy alone as the first treatment for metastatic triple-negative breast cancer or triple-negative breast cancer that has come back in the breast area but can't be removed with surgery, with high levels of the PD-L1 protein. Read more...

Moderators

Does Insulin Resistance Contribute to Worse Breast Cancer Prognosis in Black Women?
May 18, 2020
A study suggests that insulin resistance may be part of the reason why black women have worse breast cancer prognoses than white women. Read more...

Moderators

Six Months Seems Optimal for Follow-Up Imaging of 'Probably Benign' Breast Lesions
May 26, 2020
BI-RADS category 3 breast lesions should have follow-up imaging at least 6 months after the lesions are found to ensure that the lesions are not cancer, according to a study. Read more...

Moderators

Experimental Pyrotinib and Xeloda Regimen Better Than Tykerb and Xeloda for Metastatic HER2-Positive Breast Cancer
May 26, 2020
Experimental pyrotinib and Xeloda offered better progression-free survival than Tykerb and Xeloda for people diagnosed with metastatic HER2-positive breast cancer who had previously been treated with Herceptin and chemotherapy. Read more...

Moderators

Thanks for the responses ! Waiting to hear if we get the grant to support this!

MinusTwo

Mods - Are you talking about a grant to support BCO? Or a grant to support posting research news on BCO?

I'm wondering how many answered by PM as you requested? I know I did.

Moderators

MinusTwo,

It will be a grant to form a focus group that asks for feedback on how helpful our Research News program is and ways to improve it. However, we will not know for some time whether we actually get the grant. We did have quite a few responses, and thank you all for your participation.

Going forward, please send any feedback/questions/comments regarding this in a PM to us, so that we can get this Research News thread back to news-only posts. Thank you in advance!

--The Mods

Moderators

Chemotherapy Before Surgery for Early-Stage HER2-Positive Breast Cancer Doesn't Have to Include Anthracyclin
May 28, 2020
When given with two anti-HER2 medicines, a chemotherapy regimen that didn't include an anthracycline before surgery for early-stage HER2-positive breast cancer was just as effective as a regimen that included an anthracycline and caused fewer heart problems. Read more...

Moderators

One Year of Low-Dose Xeloda After Surgery for Triple-Negative Breast Cancer Seems to Reduce Recurrence Risk
May 28, 2020
A year of low-dose Xeloda as maintenance therapy after surgery and standard chemotherapy seems to reduce recurrence risk for early-stage triple-negative breast cancer. Read more...

Moderators

Genetic Mutations Linked to Higher Breast Cancer Risk Are the Same for Black, White Women
June 2, 2020
The genetic mutations that increase breast cancer risk, including mutations in the BRCA1, BRCA2, and PALB2 genes, are the same for both black and white women, which means that currently available genetic tests are effective for black women. Read more...

Moderators

Adding Tukysa to Standard Treatment Reduces Brain Lesion Growth Risk in HER2-Positive Metastatic Breast Cancer
June 4, 2020
For people with HER2-positive breast cancer that has spread to the brain, adding Tukysa to standard treatment improved survival and reduced the risk that the brain lesions would grow. Read more...